Additional research from the vaccine manufacturers would be needed to support any changes to the dosing schedule.
Researchers provide reassurance regarding potential allergic reactions to mRNA COVID-19 vaccinations from Pfizer and Moderna.
In addition to 2 COVID-19 vaccines, the FDA approved multiple medications of import to nurse practitioners and physician assistants.
There has been a 10% decline in young children receiving their first measles/mumps/rubella (MMR) vaccination by age 16 months.
AstraZeneca assessed the immunogenicity, safety, and efficacy of their novel chimpanzee adenovirus-vectored COVID-19 vaccine, ChAdOx1 nCoV-19.
Seventy-one percent of the US public report that they would get a COVID-19 vaccine, marking an increase from 63% in September.
For patients with high-risk CVD, high-dose trivalent inactivated influenza vaccination does not reduce cardiopulmonary hospitalization or all-cause mortality.
Human papillomavirus (HPV) vaccines are safe and well tolerated in male patients, with few reports of adverse events.
Older adults are less likely to get a COVID-19 vaccine than a flu vaccine, according to the University of Michigan National Poll on Healthy Aging.
To facilitate harmonized evaluation and comparison of the efficacy of COVID-19 vaccines, study authors proposed a general set of clinical endpoints, along with considerations to guide the selection of primary endpoints.
Study authors identified and evaluated a statistical signal for an increased risk of Guillain-Barré Syndrome in days 1-42 after 2018-2019 high-dose influenza vaccine administration.
Three interventions for increased human papillomavirus vaccine coverage are cost-effective.
The much-awaited remedy to the widespread transmission of SARS-CoV-2 comes with many logistical caveats.
Study authors investigated the persistence of immune response with a single-dose of inactivated Japanese encephalitis vaccine and the interchangeability with a live-attenuated vaccine in healthy children aged 1 to 15 years.
A total of 131 cases of COVID-19 were reported in the interim analysis, with no hospitalizations or severe cases noted in participants who received the vaccine.
The placebo-controlled COVE study is investigating the efficacy and safety of mRNA-1273 at the 100mcg dose (given intramuscularly in a 2-dose series, approximately 28 days apart) in more than 30,000 adults aged 18 years and older.
The trial will continue as planned and final analysis is expected when the number of confirmed COVID-19 cases reaches 164.
Nurse practitioners (NPs) executed a 5-step vaccination program for homeless individuals in Miami-Dade County to help reduce the spread of infectious diseases.
In the event of a likely scarcity of COVID-19 vaccines, a framework must be developed to inform who should get priority.
The 2018 to 2019 influenza vaccine effectiveness was about 40% to 60% for reducing pediatric influenza A-associated hospitalizations.